Skip to main content
. 2019 Jun 6;11(6):261. doi: 10.3390/pharmaceutics11060261

Figure 2.

Figure 2

Silencing of the GFP gene expression after the treatment of MDA-MB-231 cells with L1/siRNA and X-tremeGENE/siRNA complexes. The visual appearance of MDA-MB-231 cells (magnification ×100) after treatment with (a) L1/anti-GFP siRNA (N/P 8/1),(b) L1/anti-GFP siRNA (N/P 16/1), (c) x-tremeGENE/anti-GFP siRNA, (d) L1/mock siRNA (N/P 8/1), (e) L1/mock siRNA (N/P 16/1), (f) x-tremeGENE/mock siRNA complexes (200 nM siRNA), and (g) intact cells. (h) Quantitative analysis of GFP gene expression, ** p < 0.01, *** p < 0.001 when compared with cells treated by mock siRNA-complexes.